Kodiak’s Zenkuda Put 54% of Wet AMD Patients on Six-Month Dosing, Four Years After an Extended-Dosing Miss
The molecule that failed on long intervals in 2022 now holds vision with most patients on six-month dosing.
Ophthalmology
Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used
QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 … Read more
The Biosimilar Was Too Cheap to Sell. So the Price Went Up Fourfold.
Byooviz relaunched in the US at an average sales price of $1,190, roughly four times its previous level and above the originator it references.
Wet AMD’s Problem Was Never the Drug. It Was the Injections.
Susvimo won a CHMP recommendation as Europe’s first continuous-delivery wet AMD treatment, replacing monthly eye injections with two implant refills a year.
The Cheapest Drug in Retina Just Became a Branded Product
LYTENAVA becomes the first FDA-approved ophthalmic bevacizumab for wet AMD, with 12 years of exclusivity, on a molecule already used in most first-line treatment.
PRIMA Can Be Sold in 30 Countries Tomorrow. Reimbursement Is the Real Timeline.
Science Corp’s retinal implant won a CE mark for sale across 30 European countries, after trial patients gained a mean 25.5 letters of visual acuity.